Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer

Abstract Purpose Hormone receptor-positive breast cancer is characterized by the expression of estrogen receptor (ER) or progesterone receptor (PR), it is generally associated with less aggressive clinical features and more favorable prognostic outcomes, primarily due to the effectiveness of endocri...

Full description

Bibliographic Details
Published in:	BMC Cancer
Main Authors:	Zhengjia Lu, Jiao Yang, Yang Feng, Jia Ming
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Subjects:	Estrogen receptor Progesterone receptor Proteomic analysis Prognosis
Online Access:	https://doi.org/10.1186/s12885-025-14451-y

Similar Items

Genetic and clinical landscape of ER + /PR- breast cancer in China
by: Danian Dai, et al.
Published: (2023-12-01)

Tumor Ki-67, ER and PR, and antibodies against estradiol and progesterone in breast cancer patients
by: A. N. Glushkov, et al.
Published: (2023-09-01)

Prognostic significance of ER-to-PR difference in ER+/HER2- early breast cancer
by: Xiaoyan Wu, et al.
Published: (2024-10-01)

Relationship between p53 protein and ER, PR status in breast cancer tissue
by: Fang Zhang
Published: (2025-01-01)

Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
by: Haizhu Chen, et al.
Published: (2024-06-01)

Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer
by: Zhengjia Lu, et al.
Published: (2025-06-01)

Prognostic significance of steroid hormone receptors (ER and PR) in primary operable breast cancer
by: Kanjer Ksenija, et al.
Published: (2002-01-01)

Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest
by: Zühal GÜCİN, et al.
Published: (2015-08-01)

<i>f</i>HER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
by: Maria Soares, et al.
Published: (2022-06-01)

Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2− breast cancer: a retrospective cohort study
by: Yiqun Xie, et al.
Published: (2022-10-01)

CORRELATION OF ESTROGEN RECEPTOR(ER), PROGESTERONE RECEPTOR(PR) AND HER2/NEU EXPRESSION WITH CLINICOPATHOLOGICAL PARAMETERS IN PRIMARY BREAST CARCINOMA -A STUDY OF 175 CASES
by: Hiral Samir Shah, et al.
Published: (2020-06-01)

Androgen receptor in relation to progesterone receptor (AR/PR ratio) in non-metastatic hormonal positive, Her2neu negative breast cancer
by: Maged A.F. Amine, et al.
Published: (2024-01-01)

Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer—An Immunohistochemical Assessment
by: Stanisław Przewoźny, et al.
Published: (2024-02-01)

Prognostic Impact of Low Estrogen and Progesterone Positivity in Luminal B (HER2 Negative) Breast Cancer
by: Jasmina Rajc, et al.
Published: (2018-01-01)

Subtyping of Breast Carcinoma According to ER/PR and HER2/neu Expression: A Cross-sectional Study from Southern Part of Assam, India
by: Bandana Kanoo, et al.
Published: (2024-04-01)

The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer
by: Nurija Bilalović, et al.
Published: (2004-11-01)

Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone
by: James N. Ingle, et al.
Published: (2025-03-01)

Negative effect of varicocele on sperm mitochondrial dysfunction: A cross-sectional study
by: Mahshid Elahi, et al.
Published: (2024-09-01)

Personalized therapy in endometriosis — based on ERα or ERβ expression
by: Lei Zhan, et al.
Published: (2024-05-01)

<i>Synaptotagmin 13</i> Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer
by: Takahiro Ichikawa, et al.
Published: (2021-10-01)

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
by: He Dou, et al.
Published: (2024-01-01)

Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study
by: Jin-Li Wei, et al.
Published: (2018-12-01)

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
by: Xiaoyu Liu, et al.
Published: (2023-09-01)

A case-matched comparison of ER-α and ER-β expression between malignant and benign cystic pancreatic lesions
by: Lykoudis Panagis M., et al.
Published: (2025-04-01)

Assessment of ESR1, PGR, ERBB2, and MKI67 mRNA in Hormone Receptor‐Positive Early Breast Cancer: A Cross‐Sectional Study
by: Hamid Rezvani, et al.
Published: (2025-07-01)

Morphofunctional features of endometrium in women with combination of male and female factors
by: O. M. Nosenko, et al.
Published: (2019-02-01)

microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status—A Pilot Study
by: Michał Kunc, et al.
Published: (2020-08-01)

Clinical and biological significance of estrogen receptor-positive/progesterone receptor-negative in invasive breast cancer: bioinformatic analysis
by: Maryam Althobiti, et al.
Published: (2025-05-01)

Characteristics and prognosis of Her2-negative breast cancer expressing unbalanced hormone receptor
by: Tingrui Wang, et al.
Published: (2025-09-01)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
by: Mengping Long, et al.
Published: (2022-12-01)

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
by: Lingfeng Tang, et al.
Published: (2024-05-01)

High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas
by: Katherine C. Kurnit, et al.
Published: (2022-06-01)

Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer
by: Yiyu Wang, et al.
Published: (2024-06-01)

The role of progesterone and estrogen receptors in treatment choice after endometriosis surgery: A cross-sectional study
by: Tahereh Poordast, et al.
Published: (2024-09-01)

A Study of Hormonal Receptors in Esophageal Carcinoma: Northeast Indian Tertiary Cancer Center Study
by: Deepjyoti Kalita, et al.
Published: (2020-10-01)

Clinicopathological Features of Triple Negative Breast Carcinoma
by: Gowry Maram Reddy, et al.
Published: (2017-01-01)

Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis?
by: Julia Ramalho Amalio da Silva Breder, et al.
Published: (2023-01-01)

Zearalenone Promotes Uterine Development of Weaned Gilts by Interfering with Serum Hormones and Up-Regulating Expression of Estrogen and Progesterone Receptors
by: Tingting Song, et al.
Published: (2022-10-01)

Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action
by: Nayoung Kim, et al.
Published: (2025-04-01)

FEATURES OF LOCAL AND SYSTEMIC IMMUNITY, AND MORPHO-FUNCTIONAL STATE OF ENDOMETRIUM IN WOMEN WITH ANOVULATORY SYNDROME
by: E. A. Michnina, et al.
Published: (2014-07-01)